A Computational Analysis of Four RETNSNPs in Iraqi Women with Breast Cancer: A Cross-Sectional Study
DOI:
https://doi.org/10.32007/jfacmedbaghdad3148Keywords:
Breast cancer, Resistin, haploreg, swissmodel, in silicoAbstract
Background: Breast cancer is a leading malignancy in women, shaped by genetic and environmental factors. Resistin, a potential chemotherapy target, may contribute to chemoresistance when mutated. This study applies computational methods to analyze how single-nucleotide polymorphisms alter resistin’s structure and function, potentially reducing its chemotherapy sensitivity.
Methods: A total of 105 fresh blood samples were collected from patients recruited from the Oncology Teaching Hospital, Medical City, Baghdad, Iraq. between March-2020 and September-2023. Samples were classified into 3 groups of 35 samples each: control, benign and patients. DNA extraction, PCR, Sanger sequencing and computational approaches were used to analyze four resistins' polymorphisms, namely rs1862513, rs3219175, rs34788323, and rs3745367. Functional impacts were predicted using HaploReg (regulatory effects), RegulomeDB (regulatory annotations), PolyPhen-2 (pathogenicity), ProtParam (protein stability), and SWISS-MODEL (3d structural modelling). Data entry, descriptive statistics, and statistical analyses were performed using IBM SPSS Statistics version 20. The chi-squared test was applied, and a p-value <0.05 was considered statistically significant.
Results: Four Single-nucleotide polymorphisms in resistin showed notable associations with breast cancer. rs1862513: GG genotype was more frequent in malignant (40%) and benign (26%) cases versus controls (0%), indicating a strong link to disease presence. rs3219175: AA genotype showed a significant difference, while GA was non-significant. rs3745367 (phenylalanine-41-proline) (AA): identified as a risk factor (OR = 1.44) with a PolyPhen-2 score of 0.999, suggesting structural alterations in resistin. rs34788323 (arginine-65-lysine) (TT): acted as a protective factor (OR = 2.07) and was predicted benign (score = 0.015; sensitivity = 0.96; specificity = 0.79). Additionally, rs1862513 and rs3219175 may affect transcription factor binding sites.
Conclusion: In silico analysis predicts that specific resistins' polymorphisms may impair protein function, alter its structure and reduce chemotherapy sensitivity in Iraqi breast cancer patients. These variants could serve as biomarkers for personalized therapy, but need experimental validation
Received: May. 2025
Revised: Aug. 2025
Accepted: Sept 2025
Published Online: Sept 2025
Published: Oct. 2025
References
1. Alkashaf KH, Mohammed SI. Impact of Clinical Pharmacist Intervention on Chemotherapy Knowledge, Attitude, and Practice among Breast Cancer Women. J Fac Med Baghdad. 2024 Apr 1;66(1):103-9. https://doi.org/10.32007/jfacmedbagdad.6612221.
2. Alhadethy DM, Altameemi EK, Khalaf LA, Kamal AM. Pathological Nipple discharge: a comparison between breast ultrasound and mammography. J Fac Med Baghdad. 2021 May 11;63(1):18-23. https://doi.org/10.32007/jfacmedbagdad.6311813.
3. Jasim SS, Taha GI. Comparison between HSV-1 Ag detection techniques by ELISA and real-time PCR in breast cancer patients suffering from periodontitis. J Fac Med Baghdad. 2023 Oct 1;65(3):227-33. https://doi.org/10.32007/jfacmedbagdad.2105.
4. Muñoz-Palomeque A, Guerrero-Ramirez MA, Rubio-Chavez LA, Rosales-Gomez RC, Lopez-Cardona MG, Barajas-Avila VH, et al. Association of RETN and CAP1 SNPs, expression and serum resistin levels with breast cancer in Mexican women. Genetic testing and molecular biomarkers. 2018 Apr 1;22(4):209-17. https://doi.org/10.1089/gtmb.2017.0212.
5. Sahan KA, Aziz IH, Dawood SN, Al Qazzaz H. The role of resistin gene polymorphism in Iraqi breast cancer patients. Biomedicine. 2022 Dec 31;42(6):1296-300. https://doi.org/10.51248/.v42i6.2393.
6. Aziz MA, Akter T, Sarwar MS, Islam MS. The first combined meta‐analytic approach for elucidating the relationship of circulating resistin levels and RETN gene polymorphisms with colorectal and breast cancer. EJMHG. 2022 Mar 1;23(1):27. https://doi.org/10.1186/s43042-022-00240-w.
7. Farhan HM, Abougabal K, Ramadan ME, Darwish T, Eldeiry NA, Abdelkareem SA. Impacts of RETN genetic polymorphism on breast cancer development in Beni-Suef females, Egypt. Egypt. J. Immunol. 2023 Apr;30:37-46. https://doi.org/10.55133/eji.300204.
8. Elkhattabi L, Morjane I, Charoute H, Saile R, Barakat A. Computational screening and analysis of the functional and structural impact of SNPS of the human RETN gene associated to type 2 diabetes. Atherosclerosis. 2020 Dec 1;315:e199-200. https://doi.org/10.1016/j.atherosclerosis.2020.10.622.
9. PolyPhen-2. [2023 Jan 10]. Retrieved from http://genetics.bwh.harvard.edu/pph2.
10. Haploreg. [2023 Jan 10]. Retrieved from https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php.
11. SNPinfo. [2023 Jan 10]. National Institute of Environmental Health Sciences. Retrieved from https://snpinfo.niehs.nih.gov/.
12. RegulomeDB. [2023 Jan 10]. Retrieved from https://regulomedb.org/regulome-search/.
13. ExPASy. [2023 Jan 10]. Retrieved from http://www.expasy.org/.
14. Swiss-Model. [2023 Jan 10]. Retrieved from https://swissmodel.expasy.org/.
15. Deb A, Deshmukh B, Ramteke P, Bhati FK, Bhat MK. Resistin: A journey from metabolism to cancer. TRANON. 2021 Oct 1;14(10):101178. https://doi.org/10.1016/j.tranon.2021.10.
16. Issac RM, Saldanha P, Mathai JM, Mathews J, Mathews R, Kumari B, et al. Histopathological characterization of carcinoma breast with BRCA1/2 sequence variation in a tertiary care center in Kerala, South India. BBRJ. 2022 Jan 1;6(1):117-21. https://doi.org/10.4103/bbrj.bbrj_206_21.
17. Lu XJ. DSSR-enabled innovative schematics of 3D nucleic acid structures with PyMOL. Nucleic acids research. 2020 Jul 27;48(13):e74-. https://doi.org/10.1093/nar/gkaa426.
18. Capriotti E, Montanucci L, Profiti G, Rossi I, Giannuzzi D, Aresu L, et al.. Fido-SNP: the first webserver for scoring the impact of single nucleotide variants in the dog genome. Nucleic Acids Research. 2019 Jul 2;47(W1):W136-41. https://doi.org/10.1093/nar/gkz420.
19. Mohanta TK, Khan A, Hashem A, Abd_Allah EF, Al-Harrasi A. The molecular mass and isoelectric point of plant proteomes. BMC genomics. 2019 Dec;20:1-4.
https://doi.org/10.1186/s12864-019-5983-8.
20. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al.. SWISS-MODEL: homology modelling of protein structures and complexes. NAR. 2018 Jul 2;46(W1):W296-303. https://doi.org/10.1093/nar/gky427.
21. Sriram N, Mukherjee S, Sah MK. Gene expression profiling and protein-protein interaction analysis reveals the dynamic role of MCM7 in Alzheimer's disorder and breast cancer. 3 Biotech. 2022 Jul;12(7):146. https://doi.org/10.1007/s13205-022-03207-1.
22. Chi LA, Vargas MC. In silico design of peptides as potential ligands to resistin. Journal of molecular modeling. 2020 May;26:1-4. https://doi.org/10.1007/s00894-020-4338-3.
23. Sudan SK, Deshmukh SK, Poosarla T, Holliday NP, Dyess DL, Singh AP, et al.. Resistin: An inflammatory cytokine with multi-faceted roles in cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2020 Dec 1;1874(2):188419. https://doi.org/10.1016/j.bbcan.2020.188419.
24. Sahan KA, Aziz IH, Dawood SN, Abdul Razzaq SS. The Effect of Genetic Polymorphism of Resistin Gene among Iraqi Breast Cancer Women. Iraqi journal of biotechnology. 2023; 22 (1), 1-7. 565-Article Text-881-1-10-20230703.pdf
25. Tripathi D, Kant S, Pandey S, Ehtesham NZ. Resistin in metabolism, inflammation, and disease. The FEBS journal. 2020 Aug;287(15):3141-9. https://doi.org/10.1111/febs.15322.
26. Lim SW, Tan KJ, Azuraidi OM, Sathiya M, Lim EC, Lai KS, Yap WS, Afizan NA. Functional and structural analysis of non-synonymous single nucleotide polymorphisms (nsSNPs) in the MYB oncoproteins associated with human cancer. Scientific Reports. 2021 Dec 17;11(1):24206. https://doi.org/10.1038/s41598-021-03624-x.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2025 Khadija A. Sahan, Zahraa A. Sahan, Thualfiqar Gh. Turki
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution 4.0 International license..
